
    
      This is a randomized, placebo-controlled, subject and investigator blinded, multicenter,
      non-confirmatory, parallel group, proof of concept study in patients with mild to moderate
      ulcerative colitis. This study consists of a screening period of up to 4 weeks, and a 8 week
      treatment period followed by a 30 day post treatment period safety follow up. The maximum
      study duration for each such including the 4 week screening period is 16 weeks.

      At the beginning of the treatment period, subjects will be randomized to one of the two
      following treatment groups in 2:1 ratio

        -  LYS006

        -  matching placebo
    
  